Physician profile
Ashley E Dumas
NPI 1285993295
$7,162.69
in general payments reported to CMS, 2019-2025
24 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 89% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.03 · 2020: $260 · 2021: $738 · 2022: $976 · 2023: $2,126 · 2024: $1,726 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,156.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $915.59 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $773.55 | 2020-2025 | Caplyta |
| Corium, LLC | $748.37 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $703.39 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $643.47 | 2020-2025 | Trintellix |
| Alkermes, INC. | $551.15 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $531.47 | 2020-2025 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $432.86 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $331.82 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $324.95 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $239.04 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $194.85 | 2022-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $163.62 | 2022-2025 | Ingrezza |
| Neos Therapeutics, LP | $141.37 | 2019-2023 | Adzenys Xr-Odt |
| Abbvie INC. | $105.15 | 2023-2025 | Vraylar |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $88.34 | 2024 | Secuado, Xelstrym |
| Vanda Pharmaceuticals INC. | $74.89 | 2020-2023 | Fanapt, Hetlioz |
| Vertical Pharmaceuticals, LLC | $45.06 | 2025 | Relexxii |
| Almatica Pharma LLC | $44.68 | 2023 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $29.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.27 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $20.17 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.20 | 2024 | |
| Sunovion Pharmaceuticals INC. | $18.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Dumas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.